Side Effects of Estrogen for Trans Teens: A Sourced Guide for Families

TransHealthHub

Sep 13

5 min read

Key Takeaways

Estrogen therapy (also called feminizing hormone therapy) causes predictable physical changes alongside a set of monitored side effects; most reported effects are mild and managed through routine follow-up, according to Mayo Clinic.
Common short-term effects include headache, mood changes, weight changes, and breast tenderness as the body adjusts; more serious risks like blood clots and elevated liver enzymes are uncommon and are specifically what bloodwork is designed to catch early.
When spironolactone is used alongside estrogen to block testosterone, a 2019 study of 85 transgender adolescents at Boston Children's Hospital found meaningfully elevated potassium in only 2.2 percent of measurements, none of them symptomatic, and no correlation with higher doses.
A 2026 systematic review of 17 longitudinal studies covering more than 12,000 transgender adolescents found some changes in cardiovascular markers during hormone treatment, but said there is not yet enough evidence to conclude whether those changes raise long-term cardiovascular risk.
Care is not guesswork: the Endocrine Society's clinical practice guideline calls for checking pubertal development every 3 to 6 months and lab values every 6 to 12 months during treatment, plus periodic prolactin checks specific to estrogen.

The short answer

Most side effects of estrogen for transgender teens are mild and expected: breast development, redistributed body fat, softer skin, and shifts in mood or energy as the body adjusts to a new hormonal balance. The effects clinicians watch most closely, changes in cardiovascular markers, potassium levels (if an anti-androgen is used), and bone density, are tracked through scheduled bloodwork rather than left to chance. Serious complications are uncommon in the research so far. At TransHealthHub, we think families deserve the actual list of what is monitored and what current research shows, not a vague reassurance in either direction.

What estrogen does and what families should expect

Estrogen (typically 17-beta estradiol) is the hormone responsible for feminizing physical changes: breast growth, softer skin, redistributed body fat, and a slowing of muscle mass gains. Mayo Clinic lists the physical risks and complications to watch for, including blood clots, elevated triglycerides and potassium, high prolactin, weight gain, and a modestly increased breast cancer risk compared with cisgender men, though still comparable to the risk cisgender women face. Less serious effects, like headaches, mood changes, and nipple discharge, are more common and typically resolve as treatment continues.

Fertility can also be affected: Mayo Clinic notes that "the risk of permanent infertility increases with long-term use," particularly when estrogen is started before puberty, which is why clinicians discuss sperm freezing before treatment begins if biological children are a goal later. TransHealthHub's page on estrogen therapy for transfeminine teens covers what starting this medication actually looks like in practice.

For people younger than 18, Mayo Clinic is specific about the process: a young person, together with a parent or guardian, should see both a healthcare professional and a behavioral health professional experienced in transgender care before starting, so that risks, benefits, and alternatives are discussed as a family decision rather than a solo one.

Spironolactone and potassium: what a Boston Children's Hospital study found

Spironolactone, a medication that blocks testosterone, is commonly prescribed alongside estrogen, and it carries a known theoretical risk of raising blood potassium (hyperkalemia). A 2019 retrospective chart review of 85 gender-diverse adolescents at Boston Children's Hospital, with a mean age of 16.6, examined 269 potassium measurements taken during treatment. Only 2.2 percent showed elevated potassium; every elevated reading returned to normal on repeat testing, and none of the affected teens had symptoms.

Higher spironolactone doses, up to 400 milligrams per day in this cohort, were not associated with a higher hyperkalemia risk, and potassium levels actually tended to decline the longer someone stayed on treatment. The study's authors concluded that routine potassium monitoring may not be necessary for otherwise healthy patients on spironolactone, reserving it for those with other health conditions or medications that also affect potassium.

What longer-term monitoring shows so far

Physical safety data specific to transgender adolescents, rather than adults, has grown substantially in recent years. A 2026 systematic review pooled 17 longitudinal studies covering more than 12,000 transgender adolescents (mean baseline age just over 15) to look at psychological, cardiovascular, and skeletal outcomes of hormone treatment. It found changes in some cardiovascular measures, including blood pressure, cholesterol, and blood counts, but concluded there is currently insufficient evidence to say whether those changes raise the risk of cardiovascular disease.

On bone health, the review found moderate evidence that hormone therapy increases bone mineral density compared with the puberty-pausing phase that often precedes it, though some youth still showed below-average bone density scores; TransHealthHub's page on puberty blockers and bone density covers that pausing phase in more depth. The authors were candid about the limits of the evidence: most studies were short in duration, lacked comparison groups, and involved fairly uniform samples, so findings should be read with that caution in mind. Low certainty in a body of evidence is a statement about how much research exists, not proof that a treatment is unsafe.

How clinicians monitor and manage risk

Estrogen therapy is not something a young person manages alone. The Endocrine Society's clinical practice guideline recommends monitoring pubertal development every 3 to 6 months and laboratory values every 6 to 12 months during hormone treatment, with more frequent check-ins, roughly every 3 months, in the first year. For estrogen specifically, the guideline suggests periodically checking prolactin levels. The American Medical Association, American Academy of Pediatrics, American Psychological Association, and Endocrine Society continue to regard this type of care, prescribed and monitored by a qualified clinician, as medically necessary and evidence-based for adolescents with persistent gender dysphoria, a position grounded in the same monitoring approach described above rather than a stand-alone assurance.

What's monitored, and what the evidence shows so far

What's tracked	What's known so far	How it's monitored
Short-term physical effects	Usually mild: headache, mood changes, breast tenderness, weight changes	Reviewed at routine follow-up visits
Potassium (if on spironolactone)	Elevated in only 2.2 percent of readings in one adolescent cohort; none symptomatic	Periodic bloodwork, more often early in treatment
Cardiovascular markers	Some changes observed; not enough evidence yet to confirm long-term risk	Blood pressure, cholesterol, and blood count checks
Bone density	Moderate evidence that hormone therapy increases density versus the pausing phase; some youth still below average	Bone density testing as part of routine care
Fertility	Risk of reduced fertility increases with duration of use, especially if started before puberty	Fertility preservation counseling before starting

Frequently asked questions

What are the most common side effects of estrogen for trans teens? Breast development, softer skin, redistributed body fat, and shifts in mood or energy are the most commonly reported changes, alongside occasional headaches and weight changes, according to Mayo Clinic.

Is spironolactone safe to take with estrogen? Research specific to adolescents, including a Boston Children's Hospital chart review, found low rates of elevated potassium and no symptomatic cases, though clinicians still monitor for it, especially early in treatment.

How often do doctors check in during estrogen treatment? The Endocrine Society recommends checking pubertal development every 3 to 6 months and lab values every 6 to 12 months, with more frequent visits in the first year of treatment.